Pure Bioscience (PURE)
OTHER OTC:PURE
Want to see PURE full AI Analyst Report?
PURE Stock Chart & Stats
$0.05
<$0.01(1.96%)
At close: 4:00 PM EST
$0.05
<$0.01(1.96%)
Day’s Range― - ―
52-Week Range$0.04 - $0.14
Previous CloseN/A
Volume1.63K
Average Volume (3M)53.72K
Market Cap
$8.94M
Enterprise Value$14.89M
Total Cash (Recent Filing)$198.00K
Total Debt (Recent Filing)$6.14M
Price to Earnings (P/E)―
Beta-0.78
Next Earnings
Jun 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding111,886,475
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00456
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue6.18
Enterprise Value/Gross Profit0.01
Enterprise Value/Ebitda-8.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary SDC Technology & IPOwning and commercializing SDC-based antimicrobial technology with associated IP provides a durable competitive moat. It supports both product sales and licensing across food safety, healthcare and industrial channels, enabling recurring revenue streams and partner monetization over the medium term.
Historically Strong Gross MarginsSustained gross margins in the 50%+ range at the product level indicate favorable unit economics and pricing power for SDC-based solutions. If maintained, these margins enable operating leverage as sales scale and provide a structural buffer for reinvestment and R&D.
Recent Financing With Insider ParticipationA completed $1.0M private placement that included director participation materially improves near-term liquidity and signals insider confidence. Proceeds earmarked for R&D, admin and working capital reduce short-term refinancing risk and buy time to execute commercialization plans.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business is not self-funding and remains dependent on external capital. That structural cash burn elevates dilution and refinancing risk, limiting sustainable investment in commercial expansion and slowing durable scale-up.
Negative Shareholder Equity And High LeverageNegative equity and debt materially exceeding assets reflect a weakened capital structure that constrains strategic flexibility. High leverage increases vulnerability to funding shocks, raises refinancing risk, and can impede long-term partnerships or large-scale commercial initiatives.
Highly Volatile Revenue BaseLarge swings in revenue undermine predictability for margins, cash flow and capacity planning. Dependence on episodic spikes reduces confidence in sustainable growth, complicates partner agreements and forecasting, and weakens the case for sustained operational scaling.
Pure Bioscience News
PURE FAQ
What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.14 in the past 12 months.
What is Pure Bioscience’s market cap?
Pure Bioscience’s market cap is $8.94M.
When is Pure Bioscience’s upcoming earnings report date?
Pure Bioscience’s upcoming earnings report date is Jun 16, 2026 which is in 17 days.
How were Pure Bioscience’s earnings last quarter?
Pure Bioscience released its earnings results on Mar 16, 2026. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
Is Pure Bioscience overvalued?
According to Wall Street analysts Pure Bioscience’s price is currently Overvalued.
Does Pure Bioscience pay dividends?
Pure Bioscience does not currently pay dividends.
What is Pure Bioscience’s EPS estimate?
Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Bioscience have?
Pure Bioscience has 111,886,475 shares outstanding.
What happened to Pure Bioscience’s price movement after its last earnings report?
Pure Bioscience reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pure Bioscience?
Currently, no hedge funds are holding shares in PURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pure Bioscience
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
Technical Analysis
Mannatech
―
United-Guardian
―
Tantech Holdings
―
Grove Collaborative Holdings
―
Yoshitsu Co. Ltd. Sponsored ADR
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.72% Other Institutional Investors
99.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---